Last reviewed · How we verify
ezetimibe plus simvastatin
Ezetimibe plus simvastatin is a marketed combination therapy developed by the University of Cologne, positioned in the lipid-lowering market. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market competitiveness.
At a glance
| Generic name | ezetimibe plus simvastatin |
|---|---|
| Also known as | ZETIA, VYTORIN, SCH 58235, SCH 465981 |
| Sponsor | University of Cologne |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (PHASE2)
- Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis (PHASE2)
- LATAM LOWERS LDL-C (PHASE4)
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- Anti-inflammatory Effects of Simvastatin (PHASE4)
- A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
- A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038) (PHASE3)
- Eze/Simva Switch Study in Diabetics (0653A-807) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ezetimibe plus simvastatin CI brief — competitive landscape report
- ezetimibe plus simvastatin updates RSS · CI watch RSS
- University of Cologne portfolio CI